UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K
CURRENT REPORT

Pursuant to Section 13 or 15(d)
of the Securities Exchange Act of 1934

Date of Report (Date of earliest event reported): **November 23, 2026**

Acumen Pharmaceuticals, Inc.
(Exact name of Registrant as Specified in Its Charter)

Delaware	**001-40551**	**36-4108129**
(State or Other Jurisdiction of Incorporation)	(Commission File Number)	(IRS Employer Identification No.)

1210-1220 Washington Street, Suite 210 **Newton, Massachusetts**	**02465**
(Address of Principal Executive Offices)	(Zip Code)

Registrant's Telephone Number, Including Area Code: **(617) 344-4190**

(Former Name or Former Address, if Changed Since Last Report): **Not Applicable**

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instructions A.2. below):

☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class	**Trading Symbol(s)**	**Name of each exchange on which registered**
Common Stock, $0.0001 par value	ABOS	The Nasdaq Global Select Market

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☒

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers.

As previously disclosed in its Current Report on Form 8-K filed on November 5, 2026, Acumen Pharmaceuticals, Inc. (the "Company") has ceased development of sabirnetug and is evaluating its strategic options, including taking steps to implement cash conservation measures (the "Restructuring"). In connection with the Restructuring, on November 23, 2026, the board of directors of the Company (the "Board") approved the termination of employment, without cause, of each of Jim Doherty, Ph.D., the Company's President & Chief Development Officer, and Russell Barton, the Company's Chief Operating Officer, in each case effective November 30, 2026. Each of Dr. Doherty and Mr. Barton will be entitled to severance benefits in accordance with the terms, and subject to the conditions, of their respective executive employment agreements. The executive employment agreement of Dr. Doherty was filed as Exhibit 10.1 to the Company's Quarterly Report on Form 10-Q filed with the Securities and Exchange Commission (the "SEC") on May 13, 2025, and the executive employment agreement of Mr. Barton was filed as Exhibit 10.10 to the Company's Annual Report on Form 10-K filed with the SEC on March 28, 2022. Both agreements are described in the Company's definitive proxy statement filed with the SEC on April 23, 2026 (the "Proxy Statement").

On November 25, 2026, the Board appointed Matthew Zuga to serve as President of the Company, effective November 30, 2026, in addition to his current roles as Chief Financial Officer and Chief Business Officer. Biographical and other information about Mr. Zuga is included in the Proxy Statement. Mr. Zuga does not have any family relationships with any director or executive officer of the Company, and there are no arrangements or understandings with any persons pursuant to which Mr. Zuga has been appointed to his position. In addition, there have been no transactions directly or indirectly involving Mr. Zuga that would be required to be disclosed pursuant to Item 404(a) of Regulation S-K promulgated under the Securities Exchange Act of 1934, as amended. Mr. Zuga will not receive any additional compensation in connection with his appointment as President of the Company.

Item 9.01 Financial Statements and Exhibits.

(d). Exhibits

Exhibit No.	Description
104	Cover Page Interactive Data File (embedded within the Inline XBRL document).

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Company has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Acumen Pharmaceuticals, Inc.

Dated: November 25, 2026

By: /s/ Matthew Zuga

Matthew Zuga

Chief Financial Officer and Chief Business Officer